Cargando…
Exposure-response analyses of efzofitimod in patients with pulmonary sarcoidosis
Background: Preliminary evidence for efficacy in pulmonary sarcoidosis has been shown for efzofitimod. Here we present supportive evidence of efficacy based on an exposure-response analysis. Methods: Data from two studies (Phase 1, N = 24, single dose in healthy volunteers, and Phase 1b/2a, N = 25,...
Autores principales: | Walker, Gennyne, Adams, Ryan, Guy, Lauren, Chandrasekaran, Abhijeeth, Kinnersley, Nelson, Ramesh, Pavithra, Zhang, Lu, Brown, Fran, Niranjan, Vis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580085/ https://www.ncbi.nlm.nih.gov/pubmed/37854715 http://dx.doi.org/10.3389/fphar.2023.1258236 |
Ejemplares similares
-
Efzofitimod for the Treatment of Pulmonary Sarcoidosis
por: Culver, Daniel A., et al.
Publicado: (2023) -
Efzofitimod: a novel anti-inflammatory agent for sarcoidosis
por: Baughman, Robert P., et al.
Publicado: (2023) -
Interleukin-12 family cytokines and sarcoidosis
por: Ringkowski, Sabine, et al.
Publicado: (2014) -
SARS-CoV-2 infection among healthcare workers in India: Limitations of the case-control investigation
por: Niranjan, Viswanathan, et al.
Publicado: (2020) -
Leveraging in vitro and pharmacokinetic models to support bench to bedside investigation of XTMAB-16 as a novel pulmonary sarcoidosis treatment
por: Offman, Elliot, et al.
Publicado: (2023)